Structure–Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Minh T. Tran; Sandrine Grosse; Rodrigo J. Carbajo; Edgar Jacoby; Yanting Yin; Xiaodi Yu; Carol Martinez; Bart Stoops; Ludwig Cooymans; Lili Hu; Ferdinand H. Lutter; Serge Pieters; Eric Tan; Jesús Alcázar; Dirk Roymans; Herman van Vlijmen; Peter Rigaux; Sujata Sharma; Tim H. M. Jonckers

doi:10.1021/acsmedchemlett.4c00272

Abstract

Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tran et al. (2024) studied this question.

synapsesocial.com/papers/68e5dae2b6db643587570400 https://doi.org/10.1021/acsmedchemlett.4c00272

View Full Paper

Ask AI

Bookmark

Share

Structure–Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Abstract

Discussion

Cite This Study

Structure–Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Abstract

Discussion

Cite This Study

Keep reading

Keep reading